HIGHLIGHTS
- who: Mansoor Husain from the University of Toronto, Toronto, ON, Canada have published the Article: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials, in the Journal: (JOURNAL)
- what: The aim of this analysis was to better understand the CV effects of semaglutide in terms of both relative and absolute risk reduction in the broader range of T2D patient profiles that are encountered in routine clinical practice. The explanatory variables in the model were randomized treatment (semaglutide or comparator), baseline . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.